13,755 Shares in DaVita Inc. $DVA Bought by Cibc World Market Inc.

Key Points

• CIBC World Markets purchased 13,755 DaVita shares during the second quarter, worth approximately $3.06 million. Institutional investors collectively own 90.12% of the company, with BlackRock also acquiring a significant stake.
• DaVita reported quarterly EPS of $4.02, exceeding the $3.88 consensus estimate, while revenue reached $3.55 billion and rose 5.2% year over year. The company provided fiscal 2026 EPS guidance of $14.10 to $15.20.
• Analyst sentiment is mixed but improving: TD Cowen upgraded the stock to “buy,” while the average rating remains “hold” with a consensus price target of $221.75.

Cibc World Market Inc. purchased a new stake in DaVita Inc. (NYSE:DVA - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 13,755 shares of the company's stock, valued at approximately $3,060,000.

Other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in shares of DaVita in the 2nd quarter worth about $547,520,000. Arrowstreet Capital Limited Partnership raised its stake in DaVita by 114.9% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,190,000 shares of the company's stock worth $135,196,000 after buying an additional 636,191 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in DaVita in the second quarter worth about $101,127,000. Norges Bank purchased a new stake in DaVita in the fourth quarter worth about $49,164,000. Finally, Corient Private Wealth LLC boosted its position in DaVita by 1,493.1% during the 4th quarter. Corient Private Wealth LLC now owns 358,299 shares of the company's stock valued at $40,706,000 after acquiring an additional 335,809 shares in the last quarter. 90.12% of the stock is currently owned by institutional investors.

DaVita Price Performance

DVA opened at $180.34 on Thursday. The firm has a market cap of $11.51 billion, a PE ratio of 14.76, a P/E/G ratio of 0.59 and a beta of 0.88. The stock has a 50-day moving average price of $213.07 and a 200-day moving average price of $182.80. DaVita Inc. has a 1 year low of $101.00 and a 1 year high of $247.49.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 EPS for the quarter, beating the consensus estimate of $3.88 by $0.14. The company had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.50 billion. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. DaVita's revenue for the quarter was up 5.2% on a year-over-year basis. During the same period in the prior year, the firm posted $2.95 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, sell-side analysts anticipate that DaVita Inc. will post 14.57 EPS for the current year.

Insider Activity

In other news, insider Kathleen Alyce Waters sold 15,405 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the sale, the insider owned 109,194 shares in the company, valued at $22,756,029.60. This represents a 12.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 1.90% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on DVA. Oppenheimer set a $220.00 target price on DaVita in a report on Friday, August 7th. TD Cowen upgraded DaVita from a "hold" rating to a "buy" rating and lifted their price target for the company from $201.00 to $220.00 in a research report on Friday, August 7th. Weiss Ratings raised DaVita from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Wednesday, August 5th. Barclays increased their price objective on DaVita from $218.00 to $224.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 5th. Finally, Zacks Research cut shares of DaVita from a "strong-buy" rating to a "hold" rating in a report on Monday, July 6th. Four research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, DaVita presently has an average rating of "Hold" and an average price target of $221.75.

About DaVita

DaVita Inc NYSE: DVA is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source